Nitric oxide status in sickle cell anemia

Gonçalves, Raquel

doi:10.5581/1516-8484.20120063

Cited by 1 publication

(1 citation statement)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The orally administered L-glutamine supports L-arginine production, the bioavailability of which is reduced in SCD patients but is vital for the formation of nitric oxide (NO) [19]. Among its other roles, NO inhibits hemostatic activation and adhesion molecules [20]. Interestingly, in our study, some parameters of coagulation and fibrinolysis, like the thrombin-antithrombin complex and D-dimers, were reduced after higher Lglutamine supplementation.…”

Section: Higher Dose Of L-glutamine Is Protective In Terms Of Oxidati...mentioning

confidence: 55%

Stratification of βSβ+ Compound Heterozygotes Based on L-Glutamine Administration and RDW: Focusing on Disease Severity

Giannaki,

Georgatzakou,

Fortis

et al. 2023

Antioxidants

View full text Add to dashboard Cite

Sickle cell disease (SCD) is heterogeneous in terms of manifestation severity, even more so when in compound heterozygosity with beta-thalassemia. The aim of the present study was to stratify βSβ+ patient blood samples in a severity-dependent manner. Blood from thirty-two patients with HbS/β-thalassemia compound heterozygosity was examined for several parameters (e.g., hemostasis, inflammation, redox equilibrium) against healthy controls. Additionally, SCD patients were a posteriori (a) categorized based on the L-glutamine dose and (b) clustered into high-/low-RDW subgroups. The patient cohort was characterized by anemia, inflammation, and elevated coagulation. Higher-dose administration of L-glutamine was associated with decreased markers of inflammation and oxidation (e.g., intracellular reactive oxygen species) and an altered coagulation profile. The higher-RDW group was characterized by increased hemolysis, elevated markers of inflammation and stress erythropoiesis, and oxidative phenomena (e.g., membrane-bound hemoglobin). Moreover, the levels of hemostasis parameters (e.g., D-Dimers) were greater compared to the lower-RDW subgroup. The administration of higher doses of L-glutamine along with hydroxyurea seems to attenuate several features in SCD patients, probably by enhancing antioxidant power. Moreover, anisocytosis may alter erythrocytes’ coagulation processes and hemolytic propensity. This results in the disruption of the redox and pro-/anti-inflammatory equilibria, creating a positive feedback loop by inducing stress erythropoiesis and, thus, the occurrence of a mixed erythrocyte population.

show abstract

Section: Higher Dose Of L-glutamine Is Protective In Terms Of Oxidati...mentioning

confidence: 55%